NCT02183051已完成2 期
A Short Term Double-blind Trial to Compare the the Analgesic Efficacy and Tolerability of Meloxicam 15 mg, 7.5 mg, 3.75 mg and 1.875 mg Oral (Quick Tablet) Versus Placebo and Ibuprofen 400 mg and 200 mg Oral in the Treatment of Pain After Surgery of the Third Molar
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 381
- 主要终点
- Assessment of pain intensity differences (PID) on a visual analogue scale (VAS, 100 mm) from one hour onwards
研究概览
简要总结
To assess the analgesic efficacy and tolerability of meloxicam 15 mg, 7.5 mg, 3.75 mg and 1.875 mg oral (rapid release tablet) compared with placebo and ibuprofen 400 mg and 200 mg administered in a single dose, over an observation period of 6 hours in the treatment of pain after surgery of the third molar.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female aged 18 years or above
- •Patients undergoing removal of one impacted mandibular third molar under local anesthesia. (Short duration anaesthetics will be allowed, i.e. mepivacaine 3% in Italy and Spain and xylocaine in USA, both without vasoconstrictors) Only patients with type of inclusion II to IV have to be included (type II, molar in the submucosa; type III, molar partially included in the bone; type IV, molar fully included in the bone)
- •Assessment of pain must be at least 50 mm on a 100 mm visual analogue scale (VAS)
- •Patient informed consent in accordance with local legislation.
排除标准
- •Type I of inclusion (molar partially or totally erupted)
- •Known or suspected hypersensitivity to trial drug or their excipients, analgesics, antipyretics or nonsteroidal antiinflammatory drug (NSAIDs)
- •Any clinical evidence of active peptic ulceration during the last six month
- •Recurrent ulcers
- •Pregnancy or breast feeding
- •Asthma, nasal polyps, angioneurotic oedema or urticaria following the administration of aspirin or NSAIDs
- •Concomitant treatment with anti-coagulants (including heparin), lithium
- •Concomitant administration of other anti inflammatory or analgesic agents
- •Administration of any drug with analgesic properties in the 24 h previous to the administration of the study drug, except the local anesthetic for the surgery
- •Administration of any antibiotics
- •Significant perioperative complication judged by the oral surgeon
- •Clinical evidence of or known severe cardiac, hepatic, renal, metabolic, hematological disease (including bleeding disorders), mental disturbance, ulcerative colitis
- •Any other disease that could interfere with the evaluation of efficacy and safety
- •Participation in another clinical trial during this study or during the previous month
- •Previous participation in this trial
- •Patient unable to comply with the protocol
研究组 & 干预措施
Meloxicam 15 mg
Experimental
干预措施: Placebo (Drug)
Meloxicam 15 mg
Experimental
干预措施: Meloxicam 15 mg (Drug)
Meloxicam 7.5 mg
Experimental
干预措施: Meloxicam 7.5 mg (Drug)
Meloxicam 7.5 mg
Experimental
干预措施: Placebo (Drug)
Meloxicam 3.75 mg
Experimental
干预措施: Meloxicam 3.75 mg (Drug)
Meloxicam 3.75 mg
Experimental
干预措施: Placebo (Drug)
Meloxicam 1.875 mg
Experimental
干预措施: Meloxicam 1.875 mg (Drug)
Meloxicam 1.875 mg
Experimental
干预措施: Placebo (Drug)
Ibuprofen 400 mg
Active Comparator
干预措施: Placebo (Drug)
Ibuprofen 400 mg
Active Comparator
干预措施: Ibuprofen 400 mg (Drug)
Ibuprofen 200 mg
Active Comparator
干预措施: Ibuprofen 200 mg (Drug)
Ibuprofen 200 mg
Active Comparator
干预措施: Placebo (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Assessment of pain intensity differences (PID) on a visual analogue scale (VAS, 100 mm) from one hour onwards
时间窗: 60, 90, 120, 180, 240, 300 and 360 minutes after drug administration
次要结局
- Assessment of onset of analgesic action(Up to 2 hours after surgery)
- Number of withdrawals due to safety reasons(Up to 7 days after drug administration)
- Number, nature and severity of adverse events(Up to 7 days after drug administration)
- Final assessment of efficacy by patient on a 4-point verbal rating scale (VRS)(6 hours after drug administration)
- Assessment of the progress of healing of the extraction site(3-7 days after drug administration)
- Investigator's assessment of overall tolerability on a 4-point rating scale(Day 7 after drug administration)
- Number of withdrawals due to inadequate efficacy(Up to 7 days after drug administration)
- Assessment of PID on a VAS(Up to 360 minutes after drug administration)
- Number of patients with pain decrease >=50%(Up to 360 minutes after drug administration)
- Total pain relief (TOTPAR) assessed by patient (Area under the pain relief-by time curve)(Up to 360 minutes after drug administration)
- Final assessment of efficacy by investigator on a 4-point VRS(2 hours after drug administration)
- Change from baseline in laboratory values(Baseline, up to 7 days after drug administration)
- Sum of pain intensity differences (SPID)(Up to 360 minutes after drug administration)
- Assessment of maximum pain decrease on a VAS(Up to 360 minutes after drug administration)
- Patient's assessment of overall tolerability on a 4-point rating scale(Day 7 after drug administration)
- Pain relief assessed by patient on a 5-point VRS(Up to 360 minutesafter drug administration)
研究者
相似试验
已完成
2 期
Efficacy and Safety of Meloxicam vs. Naproxen Sodium in Patients With Acute Non Bacterial Pharyngitis or Pharyngo-tonsillitisPharyngitisNCT02183038Boehringer Ingelheim390
已完成
4 期
Effect of Meloxicam Tablets on Bleeding Time in Healthy SubjectsHealthyNCT02183155Boehringer Ingelheim82
已完成
2 期
Efficacy and Safety Study of Meloxicam Versus Mefenamic Acid in Patients With DysmenorrheaDysmenorrheaNCT02183025Boehringer Ingelheim337
尚未招募
2 期
Efficacy, Safety and Tolerability Study of Meloxicam Injection in Subjects After Abdominal SurgeryPain, Post-operativeNCT05950152Beijing Tide Pharmaceutical Co., Ltd108
已完成
3 期
A Study to Compare Meloxicam IM Once Daily and Meloxicam Administered Orally Once Daily in Patients With OsteoarthritisOsteoarthritisNCT00239395Boehringer Ingelheim168